Nature Communications (Mar 2018)

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

  • Julie George,
  • Vonn Walter,
  • Martin Peifer,
  • Ludmil B. Alexandrov,
  • Danila Seidel,
  • Frauke Leenders,
  • Lukas Maas,
  • Christian Müller,
  • Ilona Dahmen,
  • Tiffany M. Delhomme,
  • Maude Ardin,
  • Noemie Leblay,
  • Graham Byrnes,
  • Ruping Sun,
  • Aurélien De Reynies,
  • Anne McLeer-Florin,
  • Graziella Bosco,
  • Florian Malchers,
  • Roopika Menon,
  • Janine Altmüller,
  • Christian Becker,
  • Peter Nürnberg,
  • Viktor Achter,
  • Ulrich Lang,
  • Peter M. Schneider,
  • Magdalena Bogus,
  • Matthew G. Soloway,
  • Matthew D. Wilkerson,
  • Yupeng Cun,
  • James D. McKay,
  • Denis Moro-Sibilot,
  • Christian G. Brambilla,
  • Sylvie Lantuejoul,
  • Nicolas Lemaitre,
  • Alex Soltermann,
  • Walter Weder,
  • Verena Tischler,
  • Odd Terje Brustugun,
  • Marius Lund-Iversen,
  • Åslaug Helland,
  • Steinar Solberg,
  • Sascha Ansén,
  • Gavin Wright,
  • Benjamin Solomon,
  • Luca Roz,
  • Ugo Pastorino,
  • Iver Petersen,
  • Joachim H. Clement,
  • Jörg Sänger,
  • Jürgen Wolf,
  • Martin Vingron,
  • Thomas Zander,
  • Sven Perner,
  • William D. Travis,
  • Stefan A. Haas,
  • Magali Olivier,
  • Matthieu Foll,
  • Reinhard Büttner,
  • David Neil Hayes,
  • Elisabeth Brambilla,
  • Lynnette Fernandez-Cuesta,
  • Roman K. Thomas

DOI
https://doi.org/10.1038/s41467-018-03099-x
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

The molecular nature of large-cell neuroendocrine lung carcinomas (LCNEC) has remained unclear. Here, the authors show LCNECs represent a distinct transcriptional subgroup among lung cancers and comprise two molecular subgroups, type I (TP53 and STK11/KEAP1 alterations) and type II (TP53 and RB1 inactivation).